hologic inc. - HOLX

HOLX

Close Chg Chg %
75.01 -0.15 -0.20%

Closed Market

74.86

-0.15 (0.20%)

Volume: 3.63M

Last Updated:

Dec 4, 2025, 4:00 PM EDT

Company Overview: hologic inc. - HOLX

HOLX Key Data

Open

$74.95

Day Range

74.74 - 75.12

52 Week Range

51.90 - 80.31

Market Cap

$16.72B

Shares Outstanding

222.91M

Public Float

219.29M

Beta

0.70

Rev. Per Employee

N/A

P/E Ratio

30.10

EPS

$2.50

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

3.14M

 

HOLX Performance

1 Week
 
-0.15%
 
1 Month
 
1.03%
 
3 Months
 
12.13%
 
1 Year
 
-0.64%
 
5 Years
 
2.33%
 

HOLX Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 20
Full Ratings ➔

About hologic inc. - HOLX

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products, that focus on women’s health and well-being through early detection and treatment. It operates through the following segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment is involved in a portfolio of solutions for breast cancer care primarily in the areas of radiology, breast surgery, pathology, and treatment. The Diagnostics segment offers a range of products, which are used primarily to aid in the screening and diagnosis of human diseases. The GYN Surgical segment is involved in hysteroscopic endometrial ablation systems, tissue removal systems, fluid management systems, and laparoscopic tissue ablation systems and tools. The Skeletal Health segment covers the Horizon DXA and the Fluoroscan Insight FD mini C-arm. The company was founded by S. David Ellenbogen and Jay A. Stein in 1985 and is headquartered in Marlborough, MA.

HOLX At a Glance

Hologic, Inc.
250 Campus Drive
Marlborough, Massachusetts 01752
Phone 1-508-263-2900 Revenue 4.10B
Industry Medical Specialties Net Income 565.70M
Sector Health Technology 2025 Sales Growth 1.742%
Fiscal Year-end 09 / 2026 Employees 7,070
View SEC Filings

HOLX Valuation

P/E Current 30.099
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 27.038
Price to Sales Ratio 3.73
Price to Book Ratio 2.963
Price to Cash Flow Ratio 14.47
Enterprise Value to EBITDA 12.391
Enterprise Value to Sales 3.834
Total Debt to Enterprise Value 0.167

HOLX Efficiency

Revenue/Employee 579,985.856
Income Per Employee 80,014.144
Receivables Turnover 6.825
Total Asset Turnover 0.451

HOLX Liquidity

Current Ratio 3.754
Quick Ratio 3.058
Cash Ratio 2.254

HOLX Profitability

Gross Margin 55.771
Operating Margin 23.626
Pretax Margin 16.613
Net Margin 13.796
Return on Assets 6.226
Return on Equity 11.116
Return on Total Capital 7.371
Return on Invested Capital 7.364

HOLX Capital Structure

Total Debt to Total Equity 52.037
Total Debt to Total Capital 34.227
Total Debt to Total Assets 29.138
Long-Term Debt to Equity 51.376
Long-Term Debt to Total Capital 33.792
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Hologic Inc. - HOLX

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
4.86B 4.03B 4.03B 4.10B
Sales Growth
-13.66% -17.12% -0.00% +1.74%
Cost of Goods Sold (COGS) incl D&A
1.89B 1.81B 1.79B 1.81B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
430.10M 323.40M 309.00M 299.80M
Depreciation
89.20M 89.60M 99.30M 108.90M
Amortization of Intangibles
340.90M 233.80M 209.70M 190.90M
COGS Growth
+0.77% -4.53% -0.83% +1.18%
Gross Income
2.97B 2.22B 2.24B 2.29B
Gross Income Growth
-20.89% -25.14% +0.67% +2.19%
Gross Profit Margin
+61.07% +55.15% +55.52% +55.77%
2022 2023 2024 2025 5-year trend
SG&A Expense
1.32B 1.28B 1.27B 1.32B
Research & Development
283.40M 294.30M 272.80M 248.20M
Other SG&A
1.04B 987.60M 994.80M 1.07B
SGA Growth
+3.99% -2.99% -1.12% +3.98%
Other Operating Expense
- - - -
-
Unusual Expense
(11.50M) 233.90M 107.70M 247.20M
EBIT after Unusual Expense
1.66B 707.10M 862.50M 721.60M
Non Operating Income/Expense
23.60M 80.10M 124.70M 76.70M
Non-Operating Interest Income
12.90M 120.50M 108.70M 74.40M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
95.10M 111.10M 122.10M 117.10M
Interest Expense Growth
+1.60% +16.82% +9.90% -4.10%
Gross Interest Expense
95.10M 111.10M 122.10M 117.10M
Interest Capitalized
- - - -
-
Pretax Income
1.59B 676.10M 865.10M 681.20M
Pretax Income Growth
-32.73% -57.43% +27.95% -21.26%
Pretax Margin
+32.66% +16.78% +21.46% +16.61%
Income Tax
286.20M 220.10M 75.60M 115.50M
Income Tax - Current - Domestic
353.40M 296.50M 105.80M 217.40M
Income Tax - Current - Foreign
99.00M 32.70M 41.90M 39.70M
Income Tax - Deferred - Domestic
(139.30M) (81.50M) (58.40M) (115.10M)
Income Tax - Deferred - Foreign
(26.90M) (27.60M) (13.70M) (26.50M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
1.30B 456.00M 789.50M 565.70M
Minority Interest Expense
- - - -
-
Net Income
1.30B 456.00M 789.50M 565.70M
Net Income Growth
-30.43% -64.98% +73.14% -28.35%
Net Margin Growth
+26.77% +11.31% +19.59% +13.80%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
1.30B 456.00M 789.50M 565.70M
Preferred Dividends
- - - -
-
Net Income Available to Common
1.30B 456.00M 789.50M 565.70M
EPS (Basic)
5.1764 1.8479 3.3493 2.5014
EPS (Basic) Growth
-28.90% -64.30% +81.25% -25.32%
Basic Shares Outstanding
251.53M 246.77M 235.72M 226.16M
EPS (Diluted)
5.1291 1.8326 3.3235 2.4858
EPS (Diluted) Growth
-28.82% -64.27% +81.35% -25.21%
Diluted Shares Outstanding
253.84M 248.83M 237.55M 227.57M
EBITDA
2.08B 1.26B 1.28B 1.27B
EBITDA Growth
-28.08% -39.16% +1.17% -0.83%
EBITDA Margin
+42.74% +31.37% +31.74% +30.94%

Snapshot

Average Recommendation HOLD Average Target Price 76.80
Number of Ratings 20 Current Quarters Estimate 1.088
FY Report Date 12 / 2025 Current Year's Estimate 4.535
Last Quarter’s Earnings 1.13 Median PE on CY Estimate N/A
Year Ago Earnings 4.26 Next Fiscal Year Estimate 5.004
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 13 13 17 15
Mean Estimate 1.09 1.09 4.54 5.00
High Estimates 1.18 1.14 4.65 5.18
Low Estimate 1.02 1.03 4.37 4.75
Coefficient of Variance 4.33 3.47 1.67 2.35

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 2 2 6
OVERWEIGHT 0 0 1
HOLD 17 17 13
UNDERWEIGHT 1 1 1
SELL 0 0 0
MEAN Hold Hold Overweight

Insider Actions for Hologic Inc. - HOLX

Date Name Shares Transaction Value
Mar 3, 2025 Martin D. Madaus Director 2,206 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 3, 2025 Martin D. Madaus Director 5,535 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 3, 2025 Charles J. Dockendorff Director 3,436 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 3, 2025 Charles J. Dockendorff Director 5,535 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 3, 2025 Amy A. McBride-Wendell Director 22,594 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 3, 2025 Amy A. McBride-Wendell Director 5,535 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 3, 2025 Christiana Stamoulis Director 47,336 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 3, 2025 Christiana Stamoulis Director 5,535 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 3, 2025 Stacey D. Stewart Director 5,168 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 3, 2025 Stacey D. Stewart Director 5,535 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 3, 2025 Ludwig N. Hantson Director 12,956 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 3, 2025 Ludwig N. Hantson Director 5,535 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 3, 2025 Nanaz Mohtashami Director 4,181 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 3, 2025 Nanaz Mohtashami Director 5,535 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 13, 2025 Mark W Horvath Div. Pres., Breast & Skeletal 7,057 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 13, 2025 Mark W Horvath Div. Pres., Breast & Skeletal 2,844 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Hologic Inc. in the News